Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Trends of population-based breast cancer survival in Germany and the US: Decreasing discrepancies, but persistent survival gap of elderly patients in Germany

Authors: Bernd Holleczek, Hermann Brenner

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Studies have revealed both higher cancer survival in the US than in Germany and substantial improvement of cancer survival in the past in these countries. This population-based study aims at comparing most recent 5-year relative survival of breast cancer patients and preceding trends in both countries.

Methods

Women with a first invasive breast cancer diagnosed and followed up between 1988 and 2008 from Germany and the US (utilizing data from the Saarland Cancer Registry and the Surveillance, Epidemiology, and End Results Program, respectively) were included. Period analysis was used to derive most up-to-date 5-year relative survival and preceding survival trends according to age and stage.

Results

Since 1993, age standardized relative survival has steadily improved in Germany and the US to 83% and 88%, respectively. In the period 2005–08, relative survival of localized cancer was above 97% in both countries, and 79% and 83% for locally/regionally spread breast cancer, respectively. Prognosis of metastasized disease has remained very poor overall, with improvement essentially being restricted to younger patients. The proportion of patients diagnosed with localized breast cancer was consistently higher in the US. If adjusted for stage, the differences in relative survival between both countries diminished over time and eventually disappeared.

Conclusions

Similar survival is now observed in both countries for patients below the age of 70 years, but in Germany survival is still much lower for elderly patients. The observed trends point to treatment advances as a major cause for improved survival. However, substantial differences in mammography usage existed between both countries and might probably also account for the observed differences (to a lesser extent, also differences in health care systems, and delivery of cancer care). Encouraging, survival of breast cancer patients has improved in Germany to a much greater extent than in the US, albeit the persisting survival gap for elderly patients in Germany requires particular attention by researchers, public health authorities, and clinicians.
Literature
1.
Botha JL, Bray F, Sankila R, Parkin DM: Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003, 39: 1718-1729. 10.1016/S0959-8049(03)00118-7.CrossRefPubMed
2.
Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, Heanue M: Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010, 341: c3620-10.1136/bmj.c3620.CrossRefPubMedPubMedCentral
3.
Jemal A, Center MM, DeSantis C, Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010, 19: 1893-1907. 10.1158/1055-9965.EPI-10-0437.CrossRefPubMed
4.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.CrossRefPubMed
5.
6.
Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, Tavilla A, Santaquilani M, Sant M: Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009, 45: 1042-1066. 10.1016/j.ejca.2008.11.029.CrossRefPubMed
7.
Gondos A, Bray F, Hakulinen T, Brenner H: Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol. 2009, 20: 564-573.CrossRefPubMed
8.
9.
Rosso S, Gondos A, Zanetti R, Bray F, Zakelj M, Zagar T, Smailyte G, Ponti A, Brewster DH, Voogd AC, et al: Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer. 2010, 46: 3351-3357. 10.1016/j.ejca.2010.09.019.CrossRefPubMed
10.
Gondos A, Arndt V, Holleczek B, Stegmaier C, Ziegler H, Brenner H: Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer. 2007, 121: 395-400. 10.1002/ijc.22683.CrossRefPubMed
11.
Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Crosignani P, Danzon A, et al: Breast carcinoma survival in Europe and the United States. Cancer. 2004, 100: 715-722. 10.1002/cncr.20038.CrossRefPubMed
12.
Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, et al: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008, 9: 730-756. 10.1016/S1470-2045(08)70179-7.CrossRefPubMed
13.
Holleczek B, Arndt V, Stegmaier C, Brenner H: Trends in breast cancer survival in Germany from 1976 to 2008-A period analysis by age and stage. Cancer Epidemiol. 2011, 35: 399-406. 10.1016/j.canep.2011.01.008.CrossRefPubMed
14.
Brenner H, Stegmaier C, Ziegler H: Estimating completeness of cancer registration: an empirical evaluation of the two source capture-recapture approach in Germany. J Epidemiol Community Health. 1995, 49: 426-430. 10.1136/jech.49.4.426.CrossRefPubMedPubMedCentral
15.
Robert Koch Institute, Association of Population-based Cancer Registries in Germany (Ed): Cancer in Germany 2003–2004. Incidence and Trends. 2008, Berlin: Robert Koch Institute
16.
Surveillance, Epidemiology, and End Results (SEER) Program: Research Data 1973–2008 (released April 2011, based on the November 2010 submission). 2011, Bethesda MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch
17.
TNM Classification of Malignant Tumours. Edited by: Hermanek P, Sobin LH. 1987, Berlin: Springer, 4
18.
UICC TNM Classification of Malignant Tumours. Edited by: Sobin LH, Wittekind C. 1997, New York: Wiley-Liss, 5
19.
TNM Classification of Malignant Tumours. Edited by: Sobin LH, Wittekind C. 2002, New York: Wiley-Liss, 6
20.
Klein RJ, Schoenborn CA: Age adjustment using the 2000 projected U.S. population. Healthy People 2010. Stat Notes. 2001, 20: 1-10.
21.
Ederer F, Axtell LM, Cutler SJ: The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961, 6: 101-121.PubMed
22.
Ederer F, Heise H: Instructions to IBM 650 programmers in processing survival computations. 1959, Bethesda (MD): National Cancer Institute
23.
Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969–2008). Underlying mortality data provided by NCHS. 2011, Bethesda MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, (http://​www.​cdc.​gov/​nchs)
24.
Surveillance, Epidemiology, and End Results (SEER) Program: SEER*Stat Database: Populations - Total U.S. (1969–2009). Linked to country attributes - Total U.S. (1969–2009)). 2011, Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch
25.
Elandt-Johnson R, Johnson N: Survival Models and Data Analysis (Wiley Series in Probability and Mathematical Statistics). 1980, Indianapolis: John Wiley & Sons
26.
Baili P, Micheli A, Montanari A, Capocaccia R: Comparison of Four Methods for Estimating Complete Life Tables from Abridged Life Tables Using Mortality Data Supplied to EUROCARE-3. Math Popul Stud. 2005, 12: 183-198. 10.1080/08898480500301751.CrossRef
27.
National Center for Health Statistics: U.S. decennial life tables for 1989–91, vol 1, no. 2, methodology of the national and State life tables. 1998, Maryland: Hyattsville
28.
Brenner H, Gefeller O, Hakulinen T: Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004, 40: 326-335. 10.1016/j.ejca.2003.10.013.CrossRefPubMed
29.
Talback M, Stenbeck M, Rosen M: Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer. 2004, 40: 1361-1372. 10.1016/j.ejca.2004.02.004.CrossRefPubMed
30.
Brenner H, Hakulinen T: Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002, 20: 826-832. 10.1200/JCO.20.3.826.CrossRefPubMed
31.
Brenner H, Soderman B, Hakulinen T: Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol. 2002, 31: 456-462. 10.1093/ije/31.2.456.CrossRefPubMed
32.
Brenner H, Hakulinen T: Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006, 164: 689-696. 10.1093/aje/kwj243.CrossRefPubMed
33.
Corazziari I, Quinn M, Capocaccia R: Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004, 40: 2307-2316. 10.1016/j.ejca.2004.07.002.CrossRefPubMed
34.
Greenwood M: A report on the natural duration of cancer. 1926, HM Stationery Office: Reports on Public Health and Medical Subjects. London
35.
Holleczek B, Gondos A, Brenner H: periodR - an R package to calculate long-term cancer survival estimates using period analysis. Methods Inf Med. 2009, 48: 123-128.PubMed
36.
37.
DeNavas-Walt C, Proctor BD, Smith JC: Current Population Reports, P60-235, Income, Poverty, and Health InsuranceCoverage in the United States: 2007. 2008, Washington, DC: U.S. Census Bureau
38.
Anderson GF, Hussey PS, Frogner BK, Waters HR: Health spending in the United States and the rest of the industrialized world. Health Aff (Millwood). 2005, 24: 903-914. 10.1377/hlthaff.24.4.903.CrossRef
39.
Shapiro S, Coleman EA, Broeders M, Codd M, de Koning H, Fracheboud J, Moss S, Paci E, Stachenko S, Ballard-Barbash R: Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol. 1998, 27: 735-742. 10.1093/ije/27.5.735.CrossRefPubMed
40.
Swan J, Breen N, Coates RJ, Rimer BK, Lee NC: Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003, 97: 1528-1540. 10.1002/cncr.11208.CrossRefPubMed
41.
42.
Becker N: Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol. 2003, 129: 691-702. 10.1007/s00432-003-0494-y.CrossRefPubMed
43.
Low M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H: Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study). Dtsch Med Wochenschr. 2004, 129: 2643-2647. 10.1055/s-2004-836089.CrossRefPubMed
44.
Raum E, Rothenbacher D, Low M, Stegmaier C, Ziegler H, Brenner H: Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach. Eur J Cardiovasc Prev Rehabil. 2007, 14: 809-814. 10.1097/HJR.0b013e3282eeb308.CrossRefPubMed
45.
Malek D, Rabe P: Evaluationsbericht 2008–2009. 2012, Ergebnisse des Mammographie-Screening-Programms in Deutschland. Berlin: Kooperationsgemeinschaft Mammographie
46.
Dreier M, Borutta B, Toppich J, Bitzer EM, Walter U: Mammography and Cervical Cancer Screening - A Systematic Review about Women's Knowledge, Attitudes and Participation in Germany. Gesundheitswesen. 2011, 10.1055/s-0031-1286271.
47.
Barchielli A, Federico M, De Lisi V, Bucchi L, Ferretti S, Paci E, Ponti A, Buiatti E: In situ breast cancer: incidence trend and organised screening programmes in Italy. Eur J Cancer. 2005, 41: 1045-1050. 10.1016/j.ejca.2004.12.032.CrossRefPubMed
48.
Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996, 275: 913-918. 10.1001/jama.1996.03530360023033.CrossRefPubMed
49.
Virnig BA, Tuttle TM, Shamliyan T, Kane RL: Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010, 102: 170-178. 10.1093/jnci/djp482.CrossRefPubMed
50.
Glass AG, Lacey JV, Carreon JD, Hoover RN: Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007, 99: 1152-1161. 10.1093/jnci/djm059.CrossRefPubMed
51.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007, 356: 1670-1674. 10.1056/NEJMsr070105.CrossRefPubMed
52.
Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer. 2008, 98: 1741-1744. 10.1038/sj.bjc.6604368.CrossRefPubMedPubMedCentral
53.
Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW: Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007, 43: 2179-2193. 10.1016/j.ejca.2007.06.008.CrossRefPubMed
54.
Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Kurtz J, Sappino AP, Vlastos G: Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003, 21: 3580-3587. 10.1200/JCO.2003.02.046.CrossRefPubMed
55.
Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M: Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer. 2007, 96: 1197-1203. 10.1038/sj.bjc.6603709.CrossRefPubMedPubMedCentral
56.
Passage KJ, McCarthy NJ: Critical review of the management of early-stage breast cancer in elderly women. Intern Med J. 2007, 37: 181-189. 10.1111/j.1445-5994.2007.01269.x.CrossRefPubMed
57.
Hancke K, Denkinger MD, Konig J, Kurzeder C, Wockel A, Herr D, Blettner M, Kreienberg R: Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol. 21: 748-753.
58.
Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R: EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 2009, 45: 931-991. 10.1016/j.ejca.2008.11.018.CrossRefPubMed
59.
Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A, Coebergh JW: Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol. 2000, 35: 161-179. 10.1016/S1040-8428(00)00075-5.CrossRefPubMed
60.
Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H: Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?. Ann Oncol. 2007, 18: 1253-1259. 10.1093/annonc/mdm126.CrossRefPubMed
61.
62.
Harlan LC, Hankey BF: The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol. 2003, 21: 2232-2233. 10.1200/JCO.2003.94.023.CrossRefPubMed
63.
Merrill RM, Dearden KA: How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?. Cancer Causes Control. 2004, 15: 1027-1034. 10.1007/s10552-004-1324-5.CrossRefPubMed
64.
Wingo PA, Jamison PM, Hiatt RA, Weir HK, Gargiullo PM, Hutton M, Lee NC, Hall HI: Building the infrastructure for nationwide cancer surveillance and control–a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control. 2003, 14: 175-193. 10.1023/A:1023002322935.CrossRefPubMed
65.
Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG: Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst. 1992, 84: 872-877. 10.1093/jnci/84.11.872.CrossRefPubMed
66.
Nattinger AB, McAuliffe TL, Schapira MM: Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol. 1997, 50: 939-945. 10.1016/S0895-4356(97)00099-1.CrossRefPubMed
67.
Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985, 312: 1604-1608. 10.1056/NEJM198506203122504.CrossRefPubMed
68.
Brenner H, Holleczek B: Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificates only. Cancer Epidemiol Biomarkers Prev. 2011, 20: 2480-2486. 10.1158/1055-9965.EPI-11-0697.CrossRefPubMed
69.
Perme MP, Stare J, Esteve J: On estimation in relative survival. Biometrics. 2012, 68: 113-120. 10.1111/j.1541-0420.2011.01640.x.CrossRefPubMed
70.
Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology. 1990, 1: 43-46. 10.1097/00001648-199001000-00010.CrossRefPubMed
71.
Baili P, Micheli A, De Angelis R, Weir HK, Francisci S, Santaquilani M, Hakulinen T, Quaresmas M, Coleman MP: Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori. 2008, 94: 658-668.PubMed
Metadata
Title
Trends of population-based breast cancer survival in Germany and the US: Decreasing discrepancies, but persistent survival gap of elderly patients in Germany
Authors
Bernd Holleczek
Hermann Brenner
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-317

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter

Research article

Methylation of the KEAP1 gene promoter region in human colorectal cancer

Study protocol

Health-related quality of life among colorectal cancer patients in Malaysia: a study protocol

Study protocol

A randomised controlled trial of a theory-based intervention to improve sun protective behaviour in adolescents ('you can still be HOT in the shade'): study protocol

Research article

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study

Research article

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits